Lapuleucel-T

Drug Profile

Lapuleucel-T

Alternative Names: APC 8024; BA 7072; Cancer vaccine HER-2/neu - Dendreon; DN24-02; HER-2/neu cancer vaccine - Dendreon; Neuvenge™

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dendreon Corporation
  • Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Antigen presenting cell stimulants; ERBB 2 receptor antagonists; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Urogenital cancer
  • Phase I Breast cancer; Colorectal cancer; Ovarian cancer

Most Recent Events

  • 21 Apr 2017 Dendreon terminates the phase II NeuACT trial in Urogenital cancer (Adjuvant therapy, HER2-positive) in USA due to administrative reasons (IV) (NCT01353222)
  • 27 Aug 2015 Phase-II development for Urogenital cancer is ongoing in USA
  • 01 Jul 2015 Dendreon completes the phase II NeuACT trial in Urogenital cancer (Adjuvant therapy, HER2-positive) in USA (NCT01353222)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top